RGTLF (Argent Biopharma) Accounts Payable & Accrued Expense: $1.03 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Argent Biopharma Accounts Payable & Accrued Expense?

Argent Biopharma RGTLF Accounts Payable & Accrued Expense is $1.03 Mil as of Dec. 2025. The stock has 9 warning signs investors should review.

Argent Biopharma's quarterly accounts payable & accrued expense declined from Dec. 2024 ($2.83 Mil) to Jun. 2025 ($1.83 Mil) and declined from Jun. 2025 ($1.83 Mil) to Dec. 2025 ($1.03 Mil).

Argent Biopharma's annual accounts payable & accrued expense increased from Jun. 2024 ($0.87 Mil) to Jun. 2025 ($1.40 Mil) but then declined from Jun. 2025 ($1.40 Mil) to Jun. 2026 ($0.74 Mil).

Argent Biopharma Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Accounts Payable & Accrued Expense Chart

Argent Biopharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 1.81 0.87 1.40 0.74

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.82 2.83 1.83 1.03

Argent Biopharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $1.03 Mil mean?
Argent Biopharma (RGTLF) has a Accounts Payable & Accrued Expense of $1.03 Mil as of Dec. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Argent Biopharma and its competitors.
Is Argent Biopharma's Accounts Payable & Accrued Expense too high?
Argent Biopharma's current Accounts Payable & Accrued Expense is $1.03 Mil.
How does Argent Biopharma's Accounts Payable & Accrued Expense compare to ZTS and UTHR?
Argent Biopharma's Accounts Payable & Accrued Expense of $1.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Accounts Payable & Accrued Expense is $1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 45% below its estimated fair value. The current Accounts Payable & Accrued Expense is $1.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Accounts Payable & Accrued Expense is $1.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.